Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Investor Presentation (April 2018)
21 slides from Argent Biopharma's investor presentation, April 2018
Slide 1: Investor Presentation April 2018
ASX:MXC Investor Presentation April 2018 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by MGC Pharmaceuticals Limited (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or
Slide 3: Corporate Overview
Corporate Overview MGC Pharmaceuticals (ASX:MXC) is a medical cannabis company focused on full vertical integration through the whole medical cannabis value chain. Capital Structure MXC’s core strategy includes pharmaceutical product research and development, Active Pharmaceutical Ingredient (API) e
Slide 4: MGC's Vision & Mission
MGC’s Vision & Mission Our Vision Our Mission Be a global leader in To create a global supply chain Phytocannabinoid-based focused on creating high level products medicines within the and improving the lives of patients, by biopharmaceutical industry. developing ground-breaking treatments through in
Slide 5: Leadership Team
Leadership Team Nativ Segev Roby Zomer Brett Mitchell Dr. Ross Walker Director of Business Strategy - Managing Director and CEO Executive Chairman Non-Executive Director & Executive Director MGC Derma Head of Medical Advisory Board The founder of MGC Pharma, previously CEO Following 10 years of expe
Slide 6: MGC Pharma – Distribution channel partners
MGC Pharma – Distribution channel partners Multi-million dollar supply and distribution agreements signed Definitive Supply Agreement signed 5 Year Supply & Distribution Agreement Exclusive distribution deal for API grade Multi-year binding agreement to with Australian Pharmaceutical signed with Eur
Slide 7: Medical Advisory Board
Medical Advisory Board Professor Uri Kramer Professor David Neubauer Professor Stane Srčič Doctor Johnny Gruenfeld As Head of Department of Child, Adolescent Stane Srčič is a Professor of Certified in Israel, with clinical experience One of the few medical professionals in and Developmental Neurolog
Slide 8: Cannabinoids – Medical Potential
Cannabinoids – Medical Potential Clinical studies indicate that Cannabinoids are effective in easing symptoms of a wide range of difficult-to-control conditions, including: Prostate Seborrhea Cancer Dermatitis Sleep Epilepsy CAC Psoriasis Disorders Neurological Anti- Disorders Oncological Autoimmune
Slide 9: Company Divisions
Company Divisions MGC Pharma operates in several different segments of the Pharmaceuticals and Medical Cannabis industry, applying high standards of Quality Control (QC) through all of our divisions to assure the best we can provide to our patients and to the public MGC Pharma holds four divisions:
Slide 10: MGC Pharma - Achievements
MGC Pharma - Achievements Owner of unique IP which places the Company at the forefront of medical cannabis research and development for indications that will serve large and growing global markets MGC First Medicinal product - expected to be available in 2Q 2018 CannEpil™ is a Cannabidiol-based prod
Slide 11: The Global Pharma Market and Our Place In It
The Global Pharma Market and Our Place In It MGC Pharma aims to secure a share Global Cannabis Market Global Pharma Market of the global pharmaceutical market $60B $1,072B via its medical cannabis products. The Company is targeting large markets, where medical cannabis is Potential market likely to
Slide 12: MGC Pharma – Medical Market Potential
MGC Pharma – Medical Market Potential Evidence has shown that the market for diseases Medical Cannabis can treat will grow significantly in the coming years. Autoimmune Neurological Disorders Oncological Other Indications Anti-inflammatory Epilepsy Cachexia Psoriasis Crohn’s Disease The global epile
Slide 13: Production of CannEpil™ has commenced
Production of CannEpil™ has commenced Production of first CannEpil™ batch has commenced at European manufacturing facility. Production Commenced GMP Certification Neurological Disorders MXC’s European Medicinal Cannabis manufacturing This is the final step towards full GMP certification for the faci
Slide 14: MGC Botanic
MGC Botanic MGC Pharma’s Botanic Division engages with multiple cultivation sites to meet increasing global demand, alongside research into breeding and genetics with leading institutions and academia. Greenhouse facility Open Field Farm Collaborative Partnerships in Czech Republic in Slovenia in Sl
Slide 15: MGC Botanic: Malta Cultivation Facility
MGC Botanic: Malta Cultivation Facility Medical Cannabis cultivation and manufacturing facility license granted by Malta Government (through its economic development and foreign investment agency Malta Enterprise) MXC is one of five entities approved Cannabis legalised in Malta Agreement with Malta
Slide 16: MGC Derma: Niche Cosmetics Subsidiary
MGC Derma: Niche Cosmetics Subsidiary Positioned as one of the leading CBD cosmetics brands with distribution deals signed into multiple markets, currently in discussions to engage in new markets. MGC Derma DermaPlus CBD based cosmetics products CBD based dermatologically tested products MGC Derma C
Slide 17: MGC Nutraceuticals
MGC Nutraceuticals Emerging from a pharmaceutical grade pipeline, MGC Nutraceuticals provides premium phytocannabinoid based products that create balance and wellness within users' internal systems. Pharmaceutical Grade MGC Nutraceuticals eCommerce website launching soon. Nutraceuticals To coincide
Slide 18: MGC Group - Growth Strategy
MGC Group - Growth Strategy MGC Achieve GACP/GMP1 certification at Create R&D Platform in Drug Development, with Prof. Sircic, the Expand clinical trial program into further indications, building on European facility for Medical and API use. Pharma board and the MGC Lab team current epilepsy trial M
Slide 19: Near-Term Value Catalysts
Near-Term Value Catalysts MGC is at the forefront of a • Pending approval of Australian research license, commencement of RMIT collaboration research shift to Cannabis medications projects starting with Melanoma treatment as viable alternatives to current therapies, engaging with patient groups to e
Slide 20: Investment Summary
Investment Summary Diversified Business Model Geographically Scalable Clear Australian Strategy Industry leadership position: University Pharmaceutical products IP is transferrable globally, with active of Sydney White Paper, RMIT Medical Research and Development collaborations with global research
Slide 21: Thank You
y ) We ae ‘Thank You WA VAT BCP anna .corkag a fo &
MGC Pharmaceuticals — Investor Presentation (April 2018) on 6ix